Russian Journal of Transplantology and Artificial Organs最新文献

筛选
英文 中文
Nonselective beta-blockers in primary prophylaxis of esophageal variceal bleeding in patients with ascites waitlisted for liver transplantation 非选择性β受体阻滞剂在等待肝移植的腹水患者食管静脉曲张出血的初级预防中的作用
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-68-76
V. L. Korobka, V. Pasechnikov, R. V. Korobka, E. Pak, A. M. Shapovalov, D. Pasechnikov
{"title":"Nonselective beta-blockers in primary prophylaxis of esophageal variceal bleeding in patients with ascites waitlisted for liver transplantation","authors":"V. L. Korobka, V. Pasechnikov, R. V. Korobka, E. Pak, A. M. Shapovalov, D. Pasechnikov","doi":"10.15825/1995-1191-2023-1-68-76","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-68-76","url":null,"abstract":"Objective: to determine the efficacy of non-selective beta-blockers (NSBBs) in the primary prevention of bleeding esophageal varices and to assess their impact on the survival of patients with ascites enrolled in the liver transplant waiting list (LTWL).Materials and methods. We carried out a retrospective comparative study of cirrhotic patients with severe ascites and esophageal varices without bleeding before enrollment in the LTWL. Primary prophylaxis of variceal bleeding included the use of NSBBs (n = 97, group 1). These drugs were not used in the other patients (n = 91, group 2).Results. There were no significant differences between the groups in terms of clinical, laboratory and demographic parameters, MELD scores and Child-Turcotte-Pugh (CTP) classes for cirrhosis. Patient groups included in the study had no significant differences with respect to incidence of medium- and large-sized varices and incidence of severe ascites. Bleeding incidence was significantly lower in the NSBBs group than in the non-NSBBs group (52.6% and 95.6%, respectively, p = 0.0001).Conclusion. NSBBs constitute an efficacious therapy in primary prophylaxis of esophageal variceal bleeding, thereby saving life and preventing delisting of patients with ascites from the LTWL.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89802942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Laparoscopic partial nephrectomy in allograft kidney followed by intrarenal urinary tract reconstruction and ureteral reimplantation (clinical report) 腹腔镜肾部分切除术后肾内尿路重建及输尿管再植术(临床报告)
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-43-46
R. Trushkin, L. Artyukhina, T. K. Isaev, P. E. Medvedev, O. S. Shevcov, T. M. Klementeva
{"title":"Laparoscopic partial nephrectomy in allograft kidney followed by intrarenal urinary tract reconstruction and ureteral reimplantation (clinical report)","authors":"R. Trushkin, L. Artyukhina, T. K. Isaev, P. E. Medvedev, O. S. Shevcov, T. M. Klementeva","doi":"10.15825/1995-1191-2023-1-43-46","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-43-46","url":null,"abstract":"This paper presents a clinical case of laparoscopic nephrectomy for a large (10 cm) renal sinus mass in an allograft kidney, followed by intrarenal urinary tract reconstruction with ureteral reimplantation. The surgery had an acceptable oncological outcome, without loss of kidney function. Regardless of the volume and extent of the tumor process, the use of minimally invasive, nephron-sparing treatment techniques takes a leading position in the treatment of renal cancer in kidney recipients. Intrarenal urinary tract reconstruction allows a kidney to be saved even if the tumor is significantly large and/or inoperable.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83122799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney transplantation in a patient with familial mediterranean fever complicated by secondary amyloidosis (clinical report) 肾移植治疗家族性地中海热并发继发性淀粉样变1例(临床报告)
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-47-51
K. Tayler, S. R. Galeev
{"title":"Kidney transplantation in a patient with familial mediterranean fever complicated by secondary amyloidosis (clinical report)","authors":"K. Tayler, S. R. Galeev","doi":"10.15825/1995-1191-2023-1-47-51","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-47-51","url":null,"abstract":"The paper presents a clinical case of successful kidney transplantation (KTx) in a patient with end-stage chronic kidney disease (ESKD) resulting from familial Mediterranean fever (FMF). Pre-transplant preparation and posttransplant management tactics are presented. The authors conclude that ESKD can be effectively treated by KTx in a patient with FMF against the background of ongoing pathogenetic therapy in autoinflammation.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77436842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemodynamic evaluation of pulsatile-flow generating device in left ventricular assist devices 左室辅助装置中脉动流产生装置的血流动力学评价
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-106-112
A. Buchnev, A. P. Kuleshov, O. Y. Esipova, A. Drobyshev, N. V. Grudinin
{"title":"Hemodynamic evaluation of pulsatile-flow generating device in left ventricular assist devices","authors":"A. Buchnev, A. P. Kuleshov, O. Y. Esipova, A. Drobyshev, N. V. Grudinin","doi":"10.15825/1995-1191-2023-1-106-112","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-106-112","url":null,"abstract":"Objective: to investigate the efficiency of a device that generates pulsatile flow during constant-speed axial-flow pump operation for use in left ventricular assist devices.Materials and methods. The pulsatile flow-generating device, hereinafter referred to as «pulsator», consists of a variable hydraulic resistance made in the form of a hull. A tube of elastic biocompatible material featuring an inner diameter of 11 mm is installed inside it. In the systolic phase of the left ventricle, due to systolic pressure, the elastic tube is fully opened, minimizing resistance to blood ejection. In the diastolic phase, due to suction action of the flow pump operating in constant revolutions, the elastic tube partially closes, creating additional hydraulic resistance to blood flow, which leads to reduced diastolic aortic pressure. Comparative assessment of axial-flow pump operation in pulsating and non-pulsating modes was carried out on a hydrodynamic stand that simulated the cardiovascular system. The following indices were calculated: arterial pressure pulsation (Ip), in-pump flow pulsation (AQ), energy equivalent pressure (EEP) and surplus hemodynamic energy (SHE).Results. When comparing axial-flow pump operation in pulsatile and continuous mode, arterial pressure pulsation index, in-pump pulsation index, and SHE index increased by 2.13 ± 0.2, 3.2 ± 0.2, and 2.7 ± 0.15 times, respectively, while EER index remained unchanged.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79191033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized dosing protocol for extended-release tacrolimus in kidney transplant recipients in the early postoperative period 肾移植术后早期他克莫司缓释个体化给药方案
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-52-61
{"title":"Personalized dosing protocol for extended-release tacrolimus in kidney transplant recipients in the early postoperative period","authors":"","doi":"10.15825/1995-1191-2023-1-52-61","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-52-61","url":null,"abstract":"Objective: to develop a personalized algorithm for extended-release tacrolimus in kidney recipients and to analyze its early outcomes in comparison with a retrospective control group.Materials and methods. The first (I) control group «Standard Protocol» included 228 patients operated on at Botkin City Clinical Hospital from June 2018 to November 2021; tacrolimus was administered postoperatively in a starting standard dosage of 0.2 mg/kg. The second group (II) consisted of 75 patients operated from December 2021 to November 2022, whose postoperative treatment involved a personalized extended-release tacrolimus dosing protocol. Induction immunosuppression was similar in both groups. The target tacrolimus level in the early postoperative period was considered to be 10-12 ng/ml for all patients. The comparison criteria included incidence of Over-immunosuppression (tacrolimus C0 >15 ng/ml), incidence of acute rejection and infectious complications in the first month after surgery, incidence and duration of delayed graft function (DGF), and length of stay at the hospital.Results. Over-immunosuppression was statistically significantly lower in the personalized protocol group, with 36.7% in group I and 87.5% in group II (p < 0.001). There was also a lower incidence of early infectious complications in group II: 5.4% vs. 13.2%, however, without reaching a level of statistical significance (p = 0.088). DGF incidence in group I and group II were 25.4% (58/228) and 22.7% (17/75), respectively. The length of stay at the hospital in group II was also statistically significantly lower: 13 versus 19 bed days (p = 0.033). In both subgroups, no patient developed acute rejection in the first month after surgery (p = 1).Conclusion. The personalized dosing protocol that was developed for extended-release tacrolimus in kidney recipients achieves the target levels of the drug recommended for the early postoperative period with low risk of under-immunosuppression and associated acute graft rejection, with a significantly lower incidence of over-immunosuppression.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90058825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical case of staged treatment of combined complications of orthotopic liver transplantation 原位肝移植合并并发症分期治疗临床一例
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-07 DOI: 10.15825/1995-1191-2023-1-31-37
V. S. Dayneko, A. V. Osipov, O. Reznik, S. A. Platonov, M. A. Kiselev, M. I. Safoev, A. V. Sviatnenko, I. V. Ulyankina, I. Loginov, D. Kuzmin, V. Savello, V. Kravchuk, A. Demko, D. Kandyba, V. Manukovsky
{"title":"Clinical case of staged treatment of combined complications of orthotopic liver transplantation","authors":"V. S. Dayneko, A. V. Osipov, O. Reznik, S. A. Platonov, M. A. Kiselev, M. I. Safoev, A. V. Sviatnenko, I. V. Ulyankina, I. Loginov, D. Kuzmin, V. Savello, V. Kravchuk, A. Demko, D. Kandyba, V. Manukovsky","doi":"10.15825/1995-1191-2023-1-31-37","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-31-37","url":null,"abstract":"Hepatic artery thrombosis (HAT) following liver transplantation (LT) is a severe life-threatening complication that can lead to graft loss and mortality after LT. According to different reports, HAT incidence ranges from 2% to 9%. Modern endovascular and radiosurgical techniques allow for minimally invasive liver graft revascularization. Nonetheless, a major consequence of even a successful revascularization is ischemic cholangiopathy, which can lead to ischemic biliary strictures and anastomotic leak. The paper presents a clinical case of long-term complex treatment of combined complications of LT using minimally invasive endovascular and endoscopic techniques.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83421304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Living-related kidney transplantation: first experience at St. Luke’s Clinical Hospital 活体肾移植:圣路加临床医院的第一次经验
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-07 DOI: 10.15825/1995-1191-2023-1-38-42
{"title":"Living-related kidney transplantation: first experience at St. Luke’s Clinical Hospital","authors":"","doi":"10.15825/1995-1191-2023-1-38-42","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-38-42","url":null,"abstract":"Kidney transplantation (KT) is regarded as the most effective therapeutic approach for people with end-stage renal disease. However, for a number of reasons - constant increase in the incidence of diseases contributing to formation and development of chronic kidney disease, as well as continuing shortage of donor organs - 78-95% of patients in need of a kidney transplant do not receive the necessary treatment, and the waiting list stretches for several years. This paper presents the first outcomes of KT for chronic glomerulonephritis performed at St. Luke’s Clinical Hospital in St. Petersburg, in collaboration with the staff of Shumakov National Medical Research Center of Transplantology and Artificial Organs.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72794755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On indications for repeat liver transplantation 重复肝移植的指征
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-07 DOI: 10.15825/1995-1191-2023-1-15-23
V. V. Borovik, I. I. Tileubergenov, O. Gerasimova, D. Granov
{"title":"On indications for repeat liver transplantation","authors":"V. V. Borovik, I. I. Tileubergenov, O. Gerasimova, D. Granov","doi":"10.15825/1995-1191-2023-1-15-23","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-15-23","url":null,"abstract":"Objective: to study the causes of graft loss and indications for repeat liver transplantation (rLT).Materials and Methods. We studied the experience garnered from 250 orthotopic full-size cadaveric liver transplantations in 228 patients from 1998 to 2021. The severity of the patient’s condition at the time of intervention was estimated according to the MELD scale. Repeat surgeries were performed in 22 cases in 19 patients (analyzed group).Results. Organ preservation parameters, length of stay in intensive care unit (ICU), severity of postoperative complications in primary transplantations in general and in the analyzed group did not differ significantly. The main causes of graft loss were graft arterial insufficiency (57.9%) and hepatic artery thrombosis (21%). Severe early allograft dysfunction (EAD) and primary nonfunction accounted for 10.5%, portal vein thrombosis occurred in 5%, and chronic graft rejection was noted in 5% of cases.Conclusion. Arterial insufficiency is one of the leading causes of graft loss after liver transplantation. Early correction of arterial and biliary complications help in preserving graft viability.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86727528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Original pancreas transplant teohnique in terms of prevention of intra-abdominal purulent complications 原始胰腺移植技术在预防腹内化脓性并发症方面的应用
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-07 DOI: 10.15825/1995-1191-2023-1-24-30
V. L. Korobka, R. V. Korobka, A. M. Shapovalov, M. Kostrykin, E. Pak
{"title":"Original pancreas transplant teohnique in terms of prevention of intra-abdominal purulent complications","authors":"V. L. Korobka, R. V. Korobka, A. M. Shapovalov, M. Kostrykin, E. Pak","doi":"10.15825/1995-1191-2023-1-24-30","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-24-30","url":null,"abstract":"A clinical case of pancreas transplantation (PTx) based on an original technique is presented. The applied technique made it possible to prevent the spread and involvement of the abdominal organs in an inflammatory process caused by postoperative graft pancreatitis, and to preserve the pancreas graft.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84757491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience in the use of neutralizing monoclonal antibodies in kidney transplant recipients with COVID-19 中和性单克隆抗体在COVID-19肾移植受者中的应用体会
Russian Journal of Transplantology and Artificial Organs Pub Date : 2023-04-07 DOI: 10.15825/1995-1191-2023-1-7-14
I. G. Kim, M. Lysenko, N. Frolova, L. Artyukhina, T. Buruleva, A. Nikitina, V. Vinogradov, E. Volodina, V. I. Chervinko, E. Kryukov, M. Zubkin
{"title":"Experience in the use of neutralizing monoclonal antibodies in kidney transplant recipients with COVID-19","authors":"I. G. Kim, M. Lysenko, N. Frolova, L. Artyukhina, T. Buruleva, A. Nikitina, V. Vinogradov, E. Volodina, V. I. Chervinko, E. Kryukov, M. Zubkin","doi":"10.15825/1995-1191-2023-1-7-14","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-7-14","url":null,"abstract":" Therapy with neutralizing monoclonal antibodies (mAbs) is particularly relevant during COVID-19 outbreaks in patients at high risk of severe disease, including kidney transplant recipients (KTRs).Objective: to evaluate the efficacy and safety of neutralizing mAbs in KTRs with mild to moderate COVID-19.Materials and methods. The retrospective study included 99 KTRs who received inpatient treatment for COVID-19 between September 1 and December 31, 2021. Patients were 52.0 ± 11.5 years old (M, 47.5%). Bamlanivimab/etesevimab combination drug at a dose of 700/1400 mg was used as mAbs. To evaluate the efficacy of mAbs therapy, two groups of patients were identified. Group 1 consisted of 33 KTRs who received mAbs as one of the therapy components, while group 2 consisted of 66 patients who received no mAbs. Discharge from the hospital or death was considered as the endpoint of follow-up.Results. In group 1, after the use of mAb, progression of pulmonary process was observed less frequently than in the control group with CT1-2 transformation to CT3-4 (9.1% vs. 30.3%, respectively, p < 0.01). Group 1 KTRs differed significantly from group 2 - lower need for ICU and ventilator care (6.1% vs. 27.3% and 3% vs. 19.8%, respectively). The groups were comparable by sex, age, body mass index, Charlson Comorbidity Index (CCI) and time after kidney transplant (KTx) at the onset of the disease and by rnseline blood biochemistry parameter values at the time of hospitalization. Only C-reactive protein (CRP) and fibrinogen values were higher in the non-mAbs patients who were hospitalized later in the course of the disease (7.7 ± 3.2 days versus 4.6 ± 1.6 days in group 1, p < 0 .001). The frequency of prescription of other therapies did not differ between the compared groups. Use of mAbs significantly reduced mortality from 19.7% in KTRs in group 2 to 3% in group 1 without adverse effect on graft function. Conclusion. The use of mAbs therapy in the early stages of COVID-19 in KTRs is safe, it prevents severe COVID-19, and reduces the incidence of adverse outcomes.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76434343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信